IN2012DN00167A - - Google Patents

Info

Publication number
IN2012DN00167A
IN2012DN00167A IN167DEN2012A IN2012DN00167A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A IN 167DEN2012 A IN167DEN2012 A IN 167DEN2012A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A
Authority
IN
India
Prior art keywords
treatment
compositions
concerned
methods
multiple sclerosis
Prior art date
Application number
Other languages
English (en)
Inventor
B Gelder Frank
Alison Webster Gillian
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of IN2012DN00167A publication Critical patent/IN2012DN00167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
IN167DEN2012 2009-06-16 2010-06-16 IN2012DN00167A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (fr) 2009-06-16 2010-06-16 Compositions et procédés pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
IN2012DN00167A true IN2012DN00167A (fr) 2015-04-17

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
IN167DEN2012 IN2012DN00167A (fr) 2009-06-16 2010-06-16

Country Status (21)

Country Link
US (1) US8389479B2 (fr)
EP (1) EP2442832B1 (fr)
JP (1) JP5646617B2 (fr)
CN (1) CN102458476B (fr)
AU (1) AU2010260585B2 (fr)
BR (1) BRPI1009606A2 (fr)
CA (1) CA2688766C (fr)
CY (1) CY1115714T1 (fr)
DK (1) DK2442832T3 (fr)
ES (1) ES2521565T3 (fr)
HK (1) HK1167101A1 (fr)
HR (1) HRP20141035T1 (fr)
IL (1) IL216993A (fr)
IN (1) IN2012DN00167A (fr)
MX (1) MX2011013661A (fr)
NZ (1) NZ577731A (fr)
PL (1) PL2442832T3 (fr)
PT (1) PT2442832E (fr)
SI (1) SI2442832T1 (fr)
SM (1) SMT201400165B (fr)
WO (1) WO2010147484A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5569944B2 (ja) * 2008-04-01 2014-08-13 イネイト・イムノセラピューティクス・リミテッド 抗感染薬およびその使用
CA2816016A1 (fr) * 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Procedes de determination de differences dans l'activite alpha-4 integrine par la correlation de differences des taux de svcam et/ou de smadcam
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2926507A1 (fr) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions et methodes de protection et reparation du systeme nerveux
WO2017059486A1 (fr) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions et méthodes de traitement de l'épilepsie
WO2017070731A1 (fr) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions et méthodes pour le traitement de la maladie d'alzheimer
BR112019017724A2 (pt) 2017-03-26 2020-03-31 Mapi Pharma Ltd. Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
CA3099946A1 (fr) * 2018-05-18 2019-11-21 Universite Laval Utilisation d'un agoniste de nod2 pour le traitement, la prophylaxie et/ou le retardement de l'apparition de la sclerose en plaques et de la maladie d'alzheimer
US20210169904A1 (en) * 2018-07-03 2021-06-10 University Of Florida Research Foundation, Incorporated Microparticle systems and their use for the treatment of multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015658A1 (fr) * 1996-10-10 1998-04-16 Probe International Compositions et procedes destines au traitement d'infections virales
EP1778280A1 (fr) * 2004-07-01 2007-05-02 Kobenhavns Universitet Méthode de traitement de la sclérose en plaques et prophylaxie par traitement d'infections a leptospira
WO2008070564A1 (fr) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Utilisations du dipeptide muramyle (mdp) dans le traitement de l'inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150181A1 (fr) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions et procédés de traitement des états pathologiques liés à l'exposition au charbon
WO2008150182A1 (fr) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions et procédés de traitement de l'anthrax

Also Published As

Publication number Publication date
PL2442832T3 (pl) 2015-01-30
AU2010260585A1 (en) 2012-01-19
JP2012530132A (ja) 2012-11-29
CY1115714T1 (el) 2017-01-25
CN102458476A (zh) 2012-05-16
WO2010147484A8 (fr) 2012-07-19
HK1167101A1 (en) 2013-02-01
CA2688766A1 (fr) 2010-12-16
HRP20141035T1 (hr) 2014-12-19
MX2011013661A (es) 2012-05-22
AU2010260585A8 (en) 2012-06-14
WO2010147484A1 (fr) 2010-12-23
DK2442832T3 (da) 2014-11-10
CA2688766C (fr) 2015-06-30
EP2442832A4 (fr) 2013-07-03
BRPI1009606A2 (pt) 2016-10-11
IL216993A (en) 2016-03-31
US20100317589A1 (en) 2010-12-16
CN102458476B (zh) 2014-08-20
EP2442832B1 (fr) 2014-08-06
NZ577731A (en) 2010-08-27
EP2442832A1 (fr) 2012-04-25
ES2521565T3 (es) 2014-11-12
AU2010260585B2 (en) 2013-02-21
US8389479B2 (en) 2013-03-05
PT2442832E (pt) 2014-11-11
SI2442832T1 (sl) 2014-12-31
IL216993A0 (en) 2012-02-29
JP5646617B2 (ja) 2014-12-24
SMT201400165B (it) 2015-01-15

Similar Documents

Publication Publication Date Title
IN2012DN00167A (fr)
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
PH12014500053A1 (en) Proteasome inhibitors
EP2464724A4 (fr) Compositions et procédés d'implantation de tissu adipeux traité et produits de tissus adipeux traités
IN2012DN03883A (fr)
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
IN2012DN00971A (fr)
JO2860B1 (en) Phenylendazolyl compounds
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX2011008179A (es) Peptidos para vacuna.
MX361692B (es) Inhibidores de amida hidrolasa de ácido graso.
EP2566485A4 (fr) Compositions immunostimulatrices et procédés d'utilisation de celles-ci
EP2597949A4 (fr) Compositions submicroniques
EP2445873A4 (fr) Inhibiteurs de la protéase, compositions les comprenant et procédés d'utilisation
MY161460A (en) Elastomeric dental floss
MX2011010046A (es) Derivados de diaminopteridina.
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
MY180594A (en) Proteasome inhibitors
GEP20146006B (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide
UA42373U (en) Use of taurin and jacton as antioxidant and genome protector